Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Phase II Study of Pembrolizumab (MK-3475) versus Chemotherapy in Patients with Advanced Melanoma (KEYNOTE 002)

Trial Profile

Randomized, Phase II Study of Pembrolizumab (MK-3475) versus Chemotherapy in Patients with Advanced Melanoma (KEYNOTE 002)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Dacarbazine; Paclitaxel; Temozolomide
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-002
  • Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
  • Most Recent Events

    • 01 Apr 2021 Results comparing tumor best overall response by RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab and data was obtained from this trial published in the European Radiology
    • 23 Dec 2020 Results (n=1567) of landmark analysis assessing the long-term safety of pembrolizumab monotherapy across KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006 published in the European Journal of Cancer
    • 21 Sep 2020 Results (n=1567) of pooled analysis from KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006 evaluating long-term safety profile of pembrolizumab monotherapy and relationship with clinical outcome in advanced melanoma, presented at the 45th European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top